Dextranomer in dermatologic conditions.
Dextranomer, a high molecular weight dextran derivative, was evaluated in 43 patients, and found to be the treatment of choice for decubitus ulcers. It is useful in most leg ulcers and cutaneous wounds, and can aid in the nursing care of terminal patients with gangrene or uclerating carcinoma. Dextranomer hastens the postoperative course in dermabrasion patients. Although patients with bacterial infection show no change with dextranomer, it is useful in hastening the resolution of herpes simplex and herpes zoster lesions.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003911:Dextrans / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D011208:Powders; D012871:Skin Diseases / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*; D013529:Surgical Wound Dehiscence / Q000188:drug therapy; D014945:Wound Healing / Q000187:drug effects
D003911:Dextrans; D011208:Powders